Staging of the baboon response to group A streptococci administered intramuscularly: A descriptive study of the clinical symptoms and clinical chemical response patterns

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 167-177

  Taylor Jr , Fletcher B ^a,b,c,d   Bryant, Amy E ^a,b,c   Blick, Kenneth E ^a,b,c   Hack, Eric ^a,b,c   Jansen, Patty M ^a,b,c   Kosanke, Stanley D ^a,b,c   Stevens, Dennis L ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Boise VA Medical Center   (United States)

^c CENTRAL LABORATORY   (Netherlands)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CLINICAL FEATURE; FEMALE; INFLAMMATION; MALE; MYOSITIS; NECROTIZING FASCIITIS; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; SEPSIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 0032795615     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520147     Document Type: Article

References (54)

1. 1. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.
2. 2. Holt LE. The diseases of infancy and childhood. New York: Appleton, 1988:888.
3. 3. Rea WJ, Wyrick WJ Jr. Necrotizing fasciitis. Ann Surg 1970;172:957-64.
4. 4. Quintiliani R, Engh GA. Overwhelming sepsis associated with group A beta hemolytic streptococci. J Bone Joint Surg Am 1971;53:1391-9.
5. 5. Aitken DR, Mackett MCT, Smith LL. The changing pattern of hemolytic streptococcal gangrene. Arch Surg 1982;117:561-7.
6. 6. Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990;22:421-9.
7. 7. Holm SE, Bergholm AM. Pathogenic aspects of an outbreak of serious streptococcal infections in Sweden 1988-1989 [abstract no L1]. In: XI Lancefield International Symposium on Streptococcal Diseases (Siena, Italy), 1990.
8. 8. Keefer CS, Ingelfinger FJ, Spink WW. Significance of hemolytic streptococcic bacteremia: a study of two hundred and forty-six patients. Arch Intern Med 1937;60:1084-90.
9. 9. Duma RJ, Weinberg AN, Medrek TF, Kunz LJ. A bacteriologic and clinical study of streptococcal bacteremia. In: Streptococcal infections. 48th ed. Baltimore: Williams & Wilkins, 1969:87-91.
10. 10. Ispahani P, Donald FE, Aveline AJ. Streptococcus pyogenes bacteremia: an old enemy subdued, but not defeated. J Infect 1988;16:37-46.
11. 11. Henkel JS, Armstrong D, Blevins A, Moody MD. Group A β-hemolytic Streptococcus bacteremia in a cancer hospital. JAMA 1970;211:983-6.
12. 12. Hable KA, Horstmeier C, Wold AD, Washington JA II. Group A β-hemolytic streptococcemia: bacteriologic and clinical study of 44 cases. Mayo Clin Proc 1973;48:336-9.
13. 13. Trence DL, Khan MY, Gerding DN. Beta-hemolytic streptococcal bacteremia in adults: association with cold weather in Minnesota. Minn Med 1981;64:675-9.
14. 14. Barg NL, Kish MA, Kauffman CA, Supena RB. Group A streptococcal bacteremia in intravenous drug abusers. Am J Med 1985;78:569-74.
15. 15. Francis J, Warren RE. Streptococcus pyogenes bacteremia in Cambridge - a review of 67 episodes. Q J Med 1988;68:603-13.
16. 16. Barnham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteremia in North Yorkshire. J Infect 1989;18:231-48.
17. 17. Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis 1991;13:8-11.
18. 18. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med 1985;145:1020-3.
19. 19. Svane S. Peracute spontaneous streptococcal myositis: a report on 2 fatal cases with review of literature. Acta Chir Scand 1971;137:155-63.
20. 20. Yoder EL, Mendez J, Khatib R. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev Infect Dis 1987;9:382-5.
21. 21. Nather A, Wong FYH, Balasubramaniam P, Pang M. Streptococcal necrotizing myositis: a rare entity. A report of two cases. Clin Orthop 1987;215:206-11.
22. 22. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992;14:2-11.
23. 23. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg 1924;9:317.
24. 24. Taylor FB Jr, Kosanke S, Randolph M, et al. Retrospective description and experimental reconstitution of three different responses of the baboon to lethal E. coli. Circ Shock 1994;42:92-103.
25. 25. Hougie C. Methods of estimating fibrinogen concentration - thrombin time test. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. New York: McGraw-Hill, 1983:1667.
26. 26. Product information: Thrombo Wellcotest (Rapid Latex Kit). Purley, UK: Wellcome Research Laboratories, 1984.
27. 27. Spayd RN, Bruschi B, Burdick BA, et al. Multilayer film elements for clinical analysis: applications to representative determinations. Clin Chem 1978;24:1343-50.
28. 28. Technical information in test methodologies. Rochester, NY: Eastman Kodak, 1985.
29. 29. Wroblewski R, LaDue JS. Serum glutamic pyruvic transaminase in cardiac and hepatic disease. Proc Soc Exp Biol Med 1956;91:569.
30. 30. Oliver IT. A spectrophotometric method for the determination of creatinine phosphokinase and myokinase. Biochem J 1955;61:116.
31. 31. Roalki KSB. An improved procedure for serum creatinine phosphokinase determination. J Lab Clin Med 1967;69:696-705.
32. 32. Pudek MR. Adrenal hormones. In: Kaplan LA, Pesce AJ, eds. Clinical chemistry, therapy, analysis and correlation. St. Louis: Mosby, 1989:672-81.
33. 33. Durst R. Electrochemistry. In: Burtis CA, Ashwood ER, eds. Tictz textbook of clinical chemistry. 2nd ed. Philadelphia: W B Saunders, 1994:179-80.
34. 34. Hinshaw LB, Brackett DJ, Archer LT, Beller BK, Wilson MF. Detection of "hyperdynamic state" of sepsis in the baboon during lethal E. coli infusion. J Trauma 1983;23:361-5.
35. 35. Boermeester MA, van Leeuwen PAM, Coyle SM, Wolbink GJ, Hack CE, Lowry SF. IL-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 1995;130:739-48.
36. 36. de Boer JP, Creasey AA, Chang A, et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with a lethal or sublethal doses of E. coli. Circ Shock 1993;39:59-67.
37. 37. van Zonneveld AJ, Veerman H, Brakenhoff JPJ, Aarden LA, Cajot JF, Pannekoek H. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins. Thromb Haemost 1987;57:82-6.
38. 38. de Boer JP, Abbink JJ, Brouwer MC, et al. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines - evidence that the liver contributes to acute phase behavior of PAI-1. Thromb Haemost 1991;65:181-5.
39. 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992;119:159-68.
40. 40. Jansen PM, Pixley RA, Brouwer MC, et al. Inhibitor of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996;87:2337-44.
41. 41. Raijmakers PGHM, Groeneveld ABJ, Rauwerda JA, et al. Transient increase in interleukin-8 and pulmonary microvascular permeability following aortic surgery. Am J Respir Crit Care Med 1995;151:698-705.
42. 42. Hack CE, Hart M, Strack van Schijndel RJM, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-42.
43. 43. Jansen PM, van Damme J, Put W, de Jong IW, Taylor FB Jr, Hack CE. Monocyte chemotactic protein 1 is released during lethal and sublethal bacteremia in baboons. J Infect Dis 1995;171:1640-2.
44. 44. Helle M. Boeije L, de Groot ER, de Vos A, Aarden LA. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991;38:47-56.
45. 45. Van der Pouw Kraan TCTM, Boeije LCM, Smecnk RJT, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995;181:775-9.
46. 46. Jansen PM, van der Pouw Kraan TCTM, de Jong IW, et al. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-γ. Blood 1996;87:5144-51.
47. 2. Cancer Immunol Immunother 1995;41:287-92.
48. 48. Stevens DL, Tweten RK, Awad MM, Rood JI, Bryant AE. Clostridial gas gangrene: evidence that alpha and theta toxins differentially modulate the immune response and induce acute tissue necrosis. J Infect Dis 1997;176:189-95.
49. 49. Bryant AE, Kehoe MA, Stevens DL. Streptococcal pyrogenic exotoxin A and streptolysin O enhance PMNL binding to protein matrixes. J Infect Dis 1992;166:165-9.
50. 50. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992;165:879-85.
51. 51. Bryant AE, Bergstrom R, Zimmerman GA, et al. Clostridium perfringens invasiveness is enhanced by effects of theta toxin upon PMNL structure and function: the roles of leukocytotoxicity and expression of CD11/ CD18 adherence glycoprotein. FEMS Immunol Med Microbiol 1993;7:321-36.
52. 52. Hirsch JG, Bernheimer AW, Weissman G. Motion picture study of the toxic action of streptolysins on leukocytes. J Exp Med 1963;118:223-7.
53. 53. Kapur V, Topouzis S, Majesky MW, et al. A conserved streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog 1993;15:327-46.
54. 54. Stevens DL, Bryant AE, Hackett SP, et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996;173:619-26.